BACKGROUND: Serologic testing for @entity1593 includes @entity8265 and endomysial antibodies. In addition to these tools, assays for deamidated gliadin peptide antibodies have been shown to have sensitivity and specificity that are comparable to @entity8265 testing, and are increasingly being used for @entity1593 testing. AIMS: The goal of this study is to evaluate the utility of deamidated gliadin peptide (DGP) testing in the setting of a negative @entity8265 ( @entity8265 ) IgA test. METHODS: We reviewed the records of all @entity1 seen at two U.S. @entity1593 referral centers and identified those who had an elevated DGP IgA and/or IgG in the setting of a negative @entity8265 IgA. Of these @entity1 , those who underwent duodenal biopsy while on a gluten-containing diet were included. @entity1 with prior biopsy-proven @entity1593 or prior @entity8265 IgA positivity were excluded. The results of the biopsy were used as the gold standard for @entity1593 diagnosis, and @entity1 with @entity194 (Marsh class 3) on duodenal biopsy were considered to have @entity1593 . RESULTS: Between the two institutions, 84 @entity1 were identified with negative @entity8265 IgA and positive DGP IgA or IgG who also had duodenal biopsies performed while maintaining a gluten-containing diet. Of these @entity1 , 13 @entity1 (15.5%; 95% CI 8.5-25.0%) were found to have @entity1593 on duodenal biopsy. CONCLUSIONS: DGP antibody testing can identify cases of @entity1593 in @entity8265 -negative individuals, although the low positive predictive value suggests that the yield may be low.

Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity194 :: ('MESH:D001284', 'Disease') :: ['villous atrophy'] @entity1593 :: ('MESH:D002446', 'Disease') :: ['celiac disease'] @entity8265 :: ('7052', 'Gene') :: ['TTG', 'tissue transglutaminase']
@entity1593 :: (MESH:D002446,Disease) :: ['Celiac Disease']
